The Medicines Company (MDCO): A Sensible Acquisition by This Healthcare Company

The separation will enable the company to focus on innovative and value businesses. It will improve the ability of each business unit to respond to market dynamics with greater focus. The strategy is surely going to improve the efficiency in the system, eventually improving revenue and enhancing the value of its established brands. The separation will also maximize the use of capital by management, consequently improving returns on assets and equity. It will deliver value to customers and shareholders of Pfizer Inc. (NYSE:PFE).

Final thoughts

The Medicines Company (NASDAQ:MDCO) enjoys a very sound financial position. Moreover, the acquisition of ProFibrix will add to revenue, making its position even stronger. Perhaps it is time you took a closer look for yourself.

Endo Health Solutions has made a recovery from its previous year losses. Its new launch will further boost its sales and increase profitability. The future for the company is bright.

Despite falling sales, Pfizer managed higher net income by improving its operating and net margins. However, it is expected that due to its new strategy, management of each division will pay more attention to market dynamics and take steps to get ahead of trends. Its current price may offer an attractive entry point.

The article A Sensible Acquisition by This Healthcare Company originally appeared on Fool.com and is written by usman iftikhar.

usman iftikhar has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

usman is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.